Anti-TNF Golimumab (CNTO 148) Continues To Show Promise In Phase 2 Rheumatoid Arthritis Study

Tue, 14 Nov 2006 02:00 PM EST

... Nearly 75 percent of patients with moderately to severely active rheumatoid arthritis (RA) receiving golimumab (CNTO 148) and methotrexate experienced at least 20 percent improvement in arthritis symptoms (ACR 20) at week 52, according to new findings presented from a double-blind, placebo-controlled, dose-ranging Phase 2 study. [click link for full article] ...